Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion
NEW YORK, March 31 -
What Actually Happened
Biogen agreed to buy Apellis Pharmaceuticals (APLS) for $5.6 billion in cash, plus undisclosed contingent milestone payments. APLS shares climbed more than 100% in a single session. the kind of move that turns a speculative biotech position into a down payment on a house. The deal prices Apellis at a substantial premium to its pre-announcement trading range, valuing the company's complement therapy franchise as something Biogen desperately needs rather than something Apellis was willing to sell. That desperation is the tell.
Here's the strategic logic in one sentence: Biogen's MS franchise is shrinking, and Apellis owns the only approved treatment for a disease that had zero options until 2023. Syfovre (pegcetacoplan). Apellis's C3 complement inhibitor. treats geographic atrophy, a progressive form of age-related macular degeneration affecting an estimated 1 million U.S. patients. It competes with AstraZeneca's Izervay, but Apellis established early commercial leadership. Apellis posted $1.0 billion in trailing-twelve-month revenue yet hasn't turned a profit, carrying a forward P/E of -157.3x as it funds the Syfovre launch and expands across complement-mediated diseases. Think of this deal as Biogen buying a restaurant doing $1 billion in sales that hasn't figured out food costs yet. but Biogen believes its operational scale can fix the margin problem. The acquisition thesis lives or dies on whether Biogen can turn Syfovre revenue into Syfovre profit while extending the complement biology platform into immunology, nephrology, and hematology.
The Catch
With APLS last quoted at $40.26, this is now pure merger arbitrage. The remaining upside is the spread between the current price and the per-share consideration implied by $5.6 billion, plus any value from contingent payments. whose triggers and amounts Biogen has not yet disclosed. That opacity matters. Cantor Fitzgerald cut its price target to $31 from $35 before the announcement; that figure now represents deal-break downside, not a fundamental view. The real risk is antitrust. The FTC has scrutinized pharma consolidation closely, with particular attention to markets where approved competitors are scarce. Geographic atrophy currently has exactly two: Syfovre and Izervay. Merging one into a larger entity doesn't reduce that number, but regulators have shown they care about bargaining power dynamics even when product count stays the same. The HSR filing date and any second-request notice are the clearest signals on close timing and deal completion probability.
Bottom Line
This is a bet on regulatory approval, not fundamentals. The 100%+ pop has already priced in the deal premium. what remains is a merger-arb spread with binary FTC risk and opaque contingent-value upside. Long holders are now in a different trade than the one they entered.
For a full fundamental breakdown of Apellis Pharmaceuticals, generate a Basis Report on APLS.
Basis Report does not hold positions in securities discussed. This is not investment advice.